Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival.
M CabezónR MalinverniJ BargayB XicoyS MarcéA GarridoM TormoL ArenillasR CollJ BorrasM J JiménezM HoyosD ValcárcelL EscodaF Vall-LloveraA GarciaL L FontE RámilaM BuschbeckLurdes Zamoranull nullPublished in: Clinical epigenetics (2021)
Our findings suggest that in a subset of specific CpGs, altered DNA methylation patterns at diagnosis may be useful as a biomarker for predicting AZA response and survival.